Lemaitre Vascular Inc.

LMAT

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001158895

A

strongest fifth of 370 graded peers in healthcare

rank 13 of 370; percentile 3.3; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	C percentile 53.4
Solvency	A percentile 8.6
Growth and financing	B percentile 24.2
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $615.7M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress, fortress balance sheet
Inputs computable	11 of 14
Graded from	filings received through Feb 26, 2026 242 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	$84.40 2026-10-23; market equity $1.9B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

We are a global provider of medical devices and human tissue cryopreservation services largely used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. We develop, manufacture, and market vascular devices to address the needs of vascular surgeons and, to a lesser degree, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Our diversified portfolio of devices consists of brand name products that are used in arteries and veins and are well known to vascular surgeons. Our principal product offerings are sold globally, primarily in the United States, Europe, Canada and Asia Pacific.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 53.4						
Gross profitability	29.0%	32.3%		51.5	368	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(4.0%)	(6.6%)	65.5	807	2025-12-31
Gross margin stability, five years	2.5 pts	2.8 pts	43.2	242	2025-12-31
Solvency, sleeve percentile 8.6					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	8.18	(0.33)	11.9	752	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	13.10x	(4.51x)	3.8	81	2025-12-31
Current ratio	12.89x	2.94x	10.2	834	2025-12-31
Growth and financing, sleeve percentile 24.2					
Revenue growth, three-year compound	15.6%	10.1%	38.3	413	2025-12-31
Free cash flow growth, three-year compound	49.8%	10.9%	12.6	96	2025-12-31
Reinvestment rate	108.7%	37.1%	27.2	104	2025-12-31
Asset growth, three years	25.6%	2.1%	17.6	700	2025-12-31
Net share issuance, one year	1.0%	2.5%	25.0	636	2026-02-19

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
8	Progyny, Inc. (PGNY)	1.9	A	
9	Exelixis, Inc. (EXEL)	2.2	A	fortress balance sheet
10	Iradimed Corp. (IRMD)	2.4	A	
11	Castle Biosciences Inc. (CSTL)	2.7	A	fortress balance sheet
12	Penumbra Inc. (PEN)	3.0	A	
13	Lemaitre Vascular Inc. (LMAT)	3.3	A	
14	Electromed, Inc. (ELMD)	3.5	A	fortress balance sheet
15	Tactile Systems Technology Inc. (TCMD)	3.8	A	fortress balance sheet
16	Corcept Therapeutics Inc. (CORT)	4.1	A	fortress balance sheet
17	Ideaya Biosciences, Inc. (IDYA)	4.3	A	
18	Tarsus Pharmaceuticals, Inc. (TARS)	4.6	A	fortress balance sheet

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(7.3%)	7.7%	42
Distance from 52-week high	(28.1%)	(31.4%)	54
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	3.9%	(1.0%)	75
Book value to price	0.22	0.28	43
Sales to price	0.13	0.30	31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	5.4%	20.5%	34
Relative strength against the sector, log excess return	(0.29)	(0.14)	42

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$26.6M
Operating cash flow, four quarters	$83.0M
Months of runway	not finite
Days since last periodic filing	82 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	$22.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$178.5M	2025-12-31	2026-02-26	10-K	26-073360
2	assets	us-gaap:Assets	$615.7M	2025-12-31	2026-02-26	10-K	26-073360
3	net income	us-gaap:NetIncomeLoss	$57.7M	2025-12-31	2026-02-26	10-K	26-073360
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$81.3M	2025-12-31	2026-02-26	10-K	26-073360
5	assets	us-gaap:Assets	$551.8M	2024-12-31	2026-02-26	10-K	26-073360
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$249.6M	2025-12-31	2026-02-26	10-K	26-073360
7	gross profit	us-gaap:GrossProfit	$150.9M	2024-12-31	2026-02-26	10-K	26-073360
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$219.9M	2024-12-31	2026-02-26	10-K	26-073360
9	gross profit	us-gaap:GrossProfit	$127.0M	2023-12-31	2026-02-26	10-K	26-073360
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$193.5M	2023-12-31	2026-02-26	10-K	26-073360
11	gross profit	us-gaap:GrossProfit	$104.9M	2022-12-31	2025-02-28	10-K	25-005637
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$161.7M	2022-12-31	2025-02-28	10-K	25-005637
13	gross profit	us-gaap:GrossProfit	$101.4M	2021-12-31	2024-02-29	10-K	24-006037
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$154.4M	2021-12-31	2024-02-29	10-K	24-006037
15	current assets	us-gaap:AssetsCurrent	$468.2M	2025-12-31	2026-02-26	10-K	26-073360
16	current liabilities	us-gaap:LiabilitiesCurrent	$36.3M	2025-12-31	2026-02-26	10-K	26-073360
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$184.7M	2025-12-31	2026-02-26	10-K	26-073360
18	operating income	us-gaap:OperatingIncomeLoss	$67.9M	2025-12-31	2026-02-26	10-K	26-073360
19	book equity	us-gaap:StockholdersEquity	$393.5M	2025-12-31	2026-02-26	10-K	26-073360
20	liabilities	us-gaap:Liabilities	$222.2M	2025-12-31	2026-02-26	10-K	26-073360
21	interest expense	us-gaap:InterestExpense	$5.2M	2025-12-31	2026-02-26	10-K	26-073360
22	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$6.8M	2025-12-31	2026-02-26	10-K	26-073360
23	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$44.1M	2024-12-31	2026-02-26	10-K	26-073360
24	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$7.0M	2024-12-31	2026-02-26	10-K	26-073360
25	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$36.8M	2023-12-31	2026-02-26	10-K	26-073360
26	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$7.3M	2023-12-31	2026-02-26	10-K	26-073360
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$25.4M	2022-12-31	2025-02-28	10-K	25-005637
28	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$3.2M	2022-12-31	2025-02-28	10-K	25-005637
29	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$10.4M	2025-12-31	2026-02-26	10-K	26-073360

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$75.2M	2025-12-31	2026-02-26	10-K	26-073360
31	income tax	us-gaap:IncomeTaxExpenseBenefit	$17.4M	2025-12-31	2026-02-26	10-K	26-073360
32	current assets	us-gaap:AssetsCurrent	$402.2M	2024-12-31	2026-02-26	10-K	26-073360
33	current liabilities	us-gaap:LiabilitiesCurrent	$30.6M	2024-12-31	2026-02-26	10-K	26-073360
34	assets	us-gaap:Assets	$346.8M	2023-12-31	2025-02-28	10-K	25-005637
35	assets	us-gaap:Assets	$310.5M	2022-12-31	2024-02-29	10-K	24-006037
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	22,778,363	2026-02-19	2026-02-26	10-K	26-073360
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	22,558,631	2025-02-24	2025-02-28	10-K	25-005637

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.